claim: ifn-α2a therapy in 5 patients with inborn errors of tlr3 and irf3 infected with sars-cov-2.
evidence_1: we report here the safety of a single subcutaneous injection of peg-ifn-α2a in two patients with ieis affecting the production of type i ifns associated with a predisposition to severe covid-19.", "the rationale for proposing ifn-α2a treatment to these two patients was based on (i) the impairment of type i ifn production by both ad tlr3 and irf3 deficiencies [2,3,4,5]; (ii) the development of severe covid-19, sometimes with a fatal outcome, in some patients with ieis affecting type i ifn production; (iii) the anosmia/ageusia in both patients, whose iei predispose to hse, and the tropism of sars-cov2 for the central nervous system, which together stressed a risk of neurological manifestations of covid-19; (iv) the high susceptibility of tlr3-deficient fibroblasts to sars-cov2 in vitro, a phenotype rescued by exogenous type i ifn; (v) the diagnosis of these two patients with covid-19 at a very early stage of clinical manifestations, placing both patients in the so-called first phase of covid-19; and (vi) the known safety profile of a single dose of peg-ifn-α2a."
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  )